|
Pfizer (PFE) and India-based biotech Biocon, said today they have
entered into an agreement on the commercialization for four Biocon
insulin products. Pfizer will have exclusive rights to commercialize
Recombinant Human Insulin, Glargin, Aspart and Lispro globally,
except in Germany, India and Malaysia.
|